American Pharmacy News Reports Stories

FlutiCare, an over-the-counter fluticasone propionate nasal spray, treats patients with allergies.

Innovus Pharmaceuticals has ordered 220,000 units of FlutiCare, putting the drug on pace to meet its planned launch for the fourth quarter of 2017. Read More »

Imprimis Pharmaceuticals responds to FDA MedWatch notice

Imprimis has safely dispensed the referenced curcumin emulsion over 30,000 times without incident.

Imprimis Pharmaceuticals Inc. recently released a statement after the MedWatch notification put forth by the U.S. Food and Drug Administration. Read More »

GlobalMed unveils cutting-edge telemedicine platform

GlobalMed provides telemedicine hardware and software in 55 nations, last year logging over 3.5 million consultations.

Presenting a quantum leap in telemedicine, Scottsdale, Arizona-based GlobalMed recently released its award-winning branded eNcounter platform, designed to streamline clinical and at-home care and even geared for interoperability with wearable devices, ensuring data based outcomes. Read More »

FDA approves AbbVie's HCV infection drug Mavyret

AbbVie noted that around 3.4 million Americans are chronically infected with HCV.

AbbVie's once-daily treatment for chronic hepatitis C virus (HCV) infection, Mavyret, has been approved by the U.S. Food and Drug Administration. Read More »

La Jolla Pharmaceutical initiates EAP for investigation drug

The Food and Drug Administration facilitates EAPs to help expedite investigational medicines.

La Jolla Pharmaceutical Co. recently initiated an expanded access program (EAP) in the United States for its investigational drug LJPC-501. Read More »

FDA grants Breakthrough Therapy Designation to lymphoma drug

The designation will help expedite the development and regulatory review.

AstraZeneca and Acerta Pharma's treatment for patients with mantle cell lymphoma who have received at least one prior therapy was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration. Read More »

Pfizer's psoriatic arthritis treatment clears advisory committee

Psoriatic arthritis is a chronic, autoimmune, inflammatory disease.

Pfizer Inc.'s proposed dose of tofacitinib for the treatment of adult patients with active psoriatic arthritis received recommendation for approval by the U.S. Food and Drug Administration’s Arthritis Advisory Committee via a 10-1 vote. Read More »

CPPA awards accreditation to PANTHERx Specialty Pharmacy

Specialty pharmacies provide services that help patients achieve desired, cost-effective outcomes.

The Center for Pharmacy Practice Accreditation has awarded PANTHERx Specialty Pharmacy a practice accreditation. Read More »

FDA grants interim approval for Mylan’s TLD formulation

Mylan's TLD formulation is the first fixed-dose combination of its type to be distributed specifically for HIV/AIDS.

International pharmaceutical provider Mylan recently obtained what it called tentative approval of its New Drug Application for an antiretroviral formula to circulate as a preferred treatment for HIV/AIDS patients in developing nations. Read More »

NYU Langone Medical Center releases results from Alzheimer's study

Results of the trial were presented in London in July at the Alzheimer’s Association International Conference.

New York University Langone Medical Center has released results of an Alzheimer’s disease study that shows combining a specific care management program with commonly prescribed drugs multiplies the drug’s ability to improve daily function by roughly 7.5 times and stalls some of the disease’s effects. Read More »

Pharmacy association's executive director responds to DIR fee report

Sheila Arquette said the study is one of many in a long line paid for by pharmacy benefit managers.

National Association of Specialty Pharmacy Executive Director Sheila Arquette recently responded to a report on direct and indirect remuneration fees commissioned by the Pharmaceutical Care Management Association. Read More »

Moleculin Biotech comments on FDA approvals for AML drugs

Moleculin Biotech specializes in developing anti-cancer drug candidates.

Moleculin Biotech Inc. recently released comments regarding recent FDA approvals for new drugs that treat acute myeloid leukemia. Read More »

Radicava attains FDA approval for ALS treatment

Service care specialists are available to assist patients in finding the closest infusion facility.

Mitsubishi Tanabe Pharma America Inc. of New Jersey has reported that Radicava (edaravone), an intravenous therapy for adults with amyotrophic lateral sclerosis (ALS), is now available in the U.S. Read More »

Aimmune Therapeutics posits tentative peanut allergy answer

Carol Ostrow | Aug 15, 2017

t Aimmune’s investigational therapy targets an immune cell subset called TH2A cells — potentially desensitizing patients to the peanut allergy.

A trial treatment for peanut allergy has attracted attention in the media, with a recent Washington state publication highlighting California-based Aimmune Therapeutics Inc.’s “AR101” as a potential immunotherapy with the ability to impact allergen-specific T cells. Read More »

FDA approves Genentech’s Zelboraf for rare blood disease

Officials noted that the method is especially useful for work with rare diseases.

The U.S. Food and Drug Administration recently accepted Genentech’s supplemental New Drug Application for Zelboraf (vemurafenib) — including breakthrough therapy designation — to address a form of Erdheim-Chester disease, a rare blood disorder. Read More »

FDA approves Mavyret for hepatitis C virus